Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 320 across all filing types
Latest filing 2025-11-18 Director's Dealing
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 100% confidence The document is a short announcement (617 characters) regarding a notification of share transactions by a person discharging managerial responsibilities (PDMR). While it concerns director dealings, the document itself is a brief press release announcing the filing of these notifications, which fits the criteria for a regulatory announcement regarding specific disclosures.
2025-11-18 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
F-3
Regulatory Filings
2025-11-10 English
6-K
Regulatory Filings
2025-11-10 English
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial update from Oculis Holding AG for the period ending September 30, 2025. It contains substantive financial data, including a 'Condensed Consolidated Statements of Financial Position' and 'Condensed Consolidated Statements of Loss', along with detailed management commentary on operational milestones and clinical trial progress. As it provides comprehensive financial results for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q3 2025
2025-11-10 Icelandic
Oculis Reports Q3 2025 Financial Results and Provides Company Update
Earnings Release Classification · 100% confidence The document is a press release titled 'Oculis Reports Q3 2025 Financial Results and Provides Company Update'. It contains quarterly financial highlights, condensed consolidated statements of financial position, and statements of loss for the period ended September 30, 2025. While it contains financial data, it is an initial announcement of quarterly results rather than a full statutory interim report. According to the filing definitions, an 'Earnings Release' (ER) is the initial announcement of quarterly/periodical financial results, which matches this document perfectly. Q3 2025
2025-11-10 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.